 |
|
Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients
Young Jip Kim, Kichan Kim, Sun Hyuk Hwang, Soon Sun Kim, Dami Lee, Jae Youn Cheong, Sung Won Cho
Clin Mol Hepatol. 2013;19(3):300-304. Published online 2013 Sep 30 DOI: https://doi.org/10.3350/cmh.2013.19.3.300
|
|
Citations to this article as recorded by
 Long-Term Hepatitis B Surface Antigen Profile and Seroclearance Following Antiviral Treatment: A Single-Center, Real-World Cohort Study
Chih-Wen Huang, Chen-Ta Yang, Pei-Yuan Su, Yang-Yuan Chen, Siou-Ping Huang, Hsu-Heng Yen
Biomedicines.2023; 11(11): 2966. CrossRef Systematic review: Clinical outcomes of discontinuation of oral antivirals in hepatitis B-related liver cirrhosis
Yuhao Yao, Jiaxin Zhang, Xiaoke Li, Xiaobin Zao, Xu Cao, Guang Chen, Yong'an Ye
Frontiers in Public Health.2022;[Epub] CrossRef Perspectives on stopping nucleos(t)ide analogues therapy in patients with chronic hepatitis B
Issam Tout, Pietro Lampertico, Thomas Berg, Tarik Asselah
Antiviral Research.2021; 185: 104992. CrossRef Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg‐Negative Chronic Hepatitis B
Florian van Bömmel, Thomas Berg
Hepatology Communications.2021; 5(10): 1632. CrossRef Challenges in the discontinuation of chronic hepatitis B antiviral agents
Apichat Kaewdech, Pimsiri Sripongpun
World Journal of Hepatology.2021; 13(9): 1042. CrossRef Hepatitis B: Wann ist eine Beendigung der Therapie mit Nukleos(t)idanaloga gerechtfertigt?
F. van Bömmel, T. Berg
Der Gastroenterologe.2021; 16(6): 417. CrossRef Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis
Samuel Anthony Lachlan Hall, Sara Vogrin, Olivia Wawryk, Gareth S Burns, Kumar Visvanathan, Vijaya Sundararajan, Alexander Thompson
Gut.2021; : gutjnl-2020-323979. CrossRef The Yin and the Yang of Treatment for Chronic Hepatitis B—When to Start, When to Stop Nucleos(t)ide Analogue Therapy
Samuel Hall, Jessica Howell, Kumar Visvanathan, Alexander Thompson
Viruses.2020; 12(9): 934. CrossRef Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop
Hyung Joon Yim, Ji Hoon Kim, Jun Yong Park, Eileen L. Yoon, Hana Park, Jung Hyun Kwon, Dong Hyun Sinn, Sae Hwan Lee, Jeong-Hoon Lee, Hyun Woong Lee
Clinical and Molecular Hepatology.2020; 26(4): 411. CrossRef KASL clinical practice guidelines for management of chronic hepatitis B
Clinical and Molecular Hepatology.2019; 25(2): 93. CrossRef 48-Week Outcome after Cessation of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patient and the Associated Factors with Relapse
Wen-xiong Xu, Qian Zhang, Xiang Zhu, Chao-shuang Lin, You-ming Chen, Hong Deng, Yong-yu Mei, Zhi-xin Zhao, Dong-ying Xie, Zhi-liang Gao, Chan Xie, Liang Peng
Canadian Journal of Gastroenterology and Hepatology.2018; 2018: 1. CrossRef Why not to stop antiviral treatment in patients with chronic hepatitis B
Sebastián Marciano, Adrián Gadano
Liver International.2018; 38(S1): 97. CrossRef Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients?
Elia Moreno-Cubero, Robert T Sánchez del Arco, Julia Peña-Asensio, Eduardo Sanz de Villalobos, Joaquín Míquel, Juan Ramón Larrubia
World Journal of Gastroenterology.2018; 24(17): 1825. CrossRef Stopping long‐term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg‐negative chronic hepatitis B
Florian van Bömmel, Thomas Berg
Liver International.2018; 38(S1): 90. CrossRef SELECTING THE MANAGEMENT OF PATIENTS WITH CHRONIC HEPATITIS B AFTER THE COMPLETION OF THE LONG-TERM ANTIVIRAL THERAPY
E. V. Esaulenko, K. A. Zakharov, I. S. Alikian, A. A. Sukhoruk, T. A. Stasishkis, A. U. Kovelenov
Journal Infectology.2018; 10(3): 108. CrossRef Discontinuation of Lamivudine Treatment in HBeAg-Negative Chronic Hepatitis B: A Pilot Study with Long-Term follow-up
Fatih Karakaya, Sevil Özer, Çağdaş Kalkan, E Ali Tüzün, Aysun Çalişkan, Onur Keskin, Gökhan Kabaçam, Senem Karatayli, Ersin Karatayli, A Mithat Bozdayi, Ramazan Idilman, Cihan Yurdaydin
Antiviral Therapy.2017; 22(7): 559. CrossRef Assessing the Durability of Entecavir-Treated Hepatitis B Using Quantitative HBsAg
Chia-Chi Wang, Kuo-Chih Tseng, Tsai-Yuan Hsieh, Tai-Chung Tseng, Hans Hsienhong Lin, Jia-Horng Kao
American Journal of Gastroenterology.2016; 111(9): 1286. CrossRef KASL clinical practice guidelines: management of chronic hepatitis B
Clinical and Molecular Hepatology.2016; 22(1): 18. CrossRef Discontinuation of oral antivirals in chronic hepatitis B: A systematic review
George Papatheodoridis, Ioannis Vlachogiannakos, Evangelos Cholongitas, Karsten Wursthorn, Christos Thomadakis, Giota Touloumi, Jörg Petersen
Hepatology.2016; 63(5): 1481. CrossRef Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B
Han Ah Lee, Yeon Seok Seo, Seung Woon Park, Sang Jung Park, Tae Hyung Kim, Sang Jun Suh, Young Kul Jung, Ji Hoon Kim, Hyunggin An, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun, Soon Ho Um
Clinical and Molecular Hepatology.2016; 22(3): 382. CrossRef Controversial Issues in Current Treatment of Chronic HBV Infection
Spyros I. Siakavellas, George V. Papatheodoridis
Current Hepatology Reports.2015; 14(3): 164. CrossRef Ten-year follow-up of hepatitis B relapse after cessation of lamivudine or telbivudine treatment in chronic hepatitis B patients
H.-Y. Pan, H.-Y. Pan, L. Chen, D.-H. Yang, H.-J. Huang, Y.-X. Tong, C.-R. Chen, J. Yan
Clinical Microbiology and Infection.2015; 21(12): 1123.e1. CrossRef Oral antiviral therapy for HBeAg negative chronic hepatitis B: better stop or continue?
Pietro Lampertico
Gut.2015; 64(4): 526. CrossRef Systematic review: cessation of long‐term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen‐negative chronic hepatitis B
M.‐L. Chang, Y.‐F. Liaw, S. J. Hadziyannis
Alimentary Pharmacology & Therapeutics.2015; 42(3): 243. CrossRef Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies
Hyoung Su Kim
World Journal of Gastroenterology.2015; 21(38): 10874. CrossRef Can Nucleos(t)ide Analogue (NA) Therapy Ever be Stopped in HBeAg-Negative Chronic Hepatitis B?
Stephanos J. Hadziyannis, Dimitrios Vassilopoulos, Vassilios Sevastianos, Emilia Hadziyannis
Current Hepatology Reports.2014; 13(3): 256. CrossRef Oral Antiviral Therapy for Chronic Hepatitis B Virus Infection: Is Continuous Treatment Needed?
Chang Hyeong Lee
Gastroenterology & Hepatology: Open Access.2014;[Epub] CrossRef
|